ID   OVAS-21
AC   CVCL_A768
SY   OVAS21
DR   Cosmic; 945376
DR   Wikidata; Q54936913
RX   CelloPub=CLPUB00096;
RX   PubMed=8980248;
CC   Population: Japanese.
CC   Doubling time: 46 hours (CelloPub=CLPUB00096).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 11
//
RX   PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2;
RA   Ichikawa, Yoshihito
RA   Yoshida, Sadao
RA   Koyama, Yumi
RA   Hirai, Misako
RA   Ishikawa, Tomoyoshi
RA   Nishida, Masato
RA   Tsunoda, Hajime
RA   Kubo, Takeshi
RA   Miwa, Masanao
RA   Uchida, Kazuhiko
RT   "Inactivation of p16/CDKN2 and p15/MTS2 genes in different
RT   histological types and clinical stages of primary ovarian tumors.";
RL   Int. J. Cancer 69:466-470(1996).
//
RX   CelloPub=CLPUB00096;
RA   Morisawa, Takayuki
RA   Kuramoto, Hiroyuki
RA   Shimoda, Takao
RA   Hamano, Mieko
RA   Kato, Yoshiki
RA   Hata, Hiroki
RT   "Establishment and characterization of a CA-125 producing cell line
RT   (OVAS-21) from a clear cell adenocarcinoma of the ovary.";
RL   Hum. Cell 1:347-347(1988).
//